Richard H. J. Beǵent

EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients.

Mark Bower, E.S. Newlands, L. Holden et al. · Journal of Clinical Oncology · 1997 · 309 citations

Clinical evidence of efficient tumor targetting based on single–chain Fv antibody selected from a combinatorial library

Richard H. J. Beǵent, Marlies J. Verhaar, Kerry Chester et al. · Nature Medicine · 1996 · 241 citations

Immunology, Immunotherapeutics, Immunotherapy +16

Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy

D.B. Smith, ES Newlands, Gordon Rustin et al. · The Lancet · 1991 · 211 citations

Antiemetic Prophylaxis, Medicine, Pharmacology +6

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours

Nicholas C. Turner, Sandra J. Strauss, Debashis Sarker et al. · British Journal of Cancer · 2010 · 193 citations · Full text

Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989

E.S. Newlands, K. D. Bagshawe, Richard H. J. Beǵent et al. · BJOG An International Journal of Obstetrics & Gynaecology · 1991 · 182 citations